PATENT CLAIM ANALYSIS

Application Number: 16333532
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-08
Patent Classification: ["424", "135100"]

Abstract:
Disclosed are an ABCG2 monoclonal antibody having the effects for resisting against tumors and for reversing drug resistance of the tumors, and uses thereof in novel tumor resisting drugs. Also disclosed is a new antigen sequence, used for inducing generation of a monoclonal antibody or a polyclonal antibody for the ABCG2. In addition, disclosed is a hybridoma for generating the ABCG2 monoclonal antibody having the effects for resisting against tumors and for reversing drug resistance of the tumors.

Claim (Index 5):
The monoclonal antibody according to  claim 1 , which is an engineered antibody.

Metadata:
- Claim Count in Document: 27.0
- Percentile: 99.0
- Lexical Diversity: 2.0
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15351418', '14729953', '13698201', '13125530', '13701151']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7576548332857996
- 35 USC 102 Novelty (BERT): 0.5143105775929925
- Combined Prediction Score: 0.733320407716519
- Mean Citation Score: 282.705238
- Max Citation Score: 307.98862
- Similarity Product: 242.3525502461076

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test